Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer

Parker L. Bussies, Matthew Schlumbrecht

Research output: Contribution to journalArticlepeer-review

Abstract

Low-grade serous ovarian carcinoma (LGSOC) is known to exhibit chemoresistance. Effective treatment options for recurrent disease are few and often limited to hormone antagonism. Combination of endocrine therapies with MEK-inhibitors displays synergism in preclinical ovarian cancer models, however. This brief communication presents the use of combination anti-estrogenic and MEK-inhibitor therapies, fulvestrant and trametinib, as treatment in a heavily pretreated patient with estrogen receptor-positive, recurrent LGSOC. The dual-therapy regimen was well tolerated and appeared to confer 9 months of progression-free survival. Further investigation is warranted to explore this effect.

Original languageEnglish (US)
Pages (from-to)e1124-e1126
JournalOncologist
Volume25
Issue number7
DOIs
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer'. Together they form a unique fingerprint.

Cite this